Ascites is the most common complication associated with cirrhosis resulting in poor quality of life, high risk of development of other complications of cirrhosis, increased morbidity and mortality associated with surgical interventions, and poor long-term outcome. Patients with cirrhosis and a first onset of ascites, have a probability of survival of 85% during the first year and 56% at 5 years without liver transplantation. Ascites is caused due to increased renal sodium retention as a result of increased activity of the renin-angiotensin-aldosterone system in response to marked vasodilation of the splanchnic circulation. The practical management of ascites involves the proper evaluation of a patient with a thorough history and physical exam. In addition, complete laboratory, ascitic fluid, and radiological tests should be performed. One of the most important steps in the initial assessment of patients with ascites is to refer the appropriate candidates for liver transplantation, as it offers a definitive cure for cirrhosis and its complications. While the initial management of uncomplicated ascites with low sodium diet and diuretic treatment is straightforward in a majority of patients, approximately 10% of patients fail to respond to diuretics and become a real therapeutic challenge. The initial treatment of choice in patients with refractory ascites is large-volume paracentesis (LVP) associated with intravenous albumin; some patients also benefit from transjugular intrahepatic portosystemic shunts (TIPS). When repeated LVP or TIPS cannot be performed, other approaches using vasoconstrictors such as midodrine can be considered although data are scarce. A newly designed automated low flow pump system (Alfapump), which is designed to move ascites from the peritoneal cavity to the urinary bladder where it is eliminated spontaneously through diuresis is promising, but the data are also limited and safety is still a matter of concern. This article focuses on the practical aspects of the evaluation and treatment of patients with ascites and cirrhosis and also discusses how to translate our current understanding of ascites pathophysiology into new treatment methods for patients with fluid retention.

1.
Ginés P, Quintero E, Arroyo V, et al: Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987;7:122-128.
2.
Planas R, Montoliu S, Ballesté B, et al: Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006;4:1385-1394.
3.
Ripoll C, Groszmann R, Garcia-Tsao G, et al: Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007;133:481-488.
4.
Ginès P, Cárdenas A, Solà E, Schrier RW: Liver disease and the kidney; in Schrier RW, Coffman TM, Falk RJ, Molitoris BA, Neilson EG (eds): Schrier's Diseases of the Kidney, ed 9. Philadelphia, Lippincott Williams & Wilkins, 2012, pp 1965-1996.
5.
Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J: Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-1157.
6.
Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V: Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol 2015;63:1272-1284.
7.
Iwakiri Y: Pathophysiology of portal hypertension. Clin Liver Dis 2014;18:281-291.
8.
Caraceni P, Domenicali M, Giannone F, Bernardi M: The role of the endocannabinoid system in liver diseases. Best Pract Res Clin Endocrinol Metab 2009;23:65-77.
9.
Wiest R, Garcia-Tsao G: Bacterial translocation (BT) in cirrhosis. Hepatology 2005;41:422-433.
10.
Riordan SM, Williams R: The intestinal flora and bacterial infection in cirrhosis. J Hepatol 2006;45:744-757.
11.
Moore KP, Wong F, Gines P, et al: The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003;38:258-266.
12.
European Association for the Study of the Liver: EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397-417.
13.
Ginès P, Cárdenas A, Arroyo V, Rodés J: Management of cirrhosis and ascites. N Engl J Med 2004;350:1646-1654.
14.
Runyon BA; AASLD Practice Guidelines Committee: Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009;49:2087-2107.
15.
McCullough AJ: Nutrition and malnutrition in liver disease; in Wolfe MM, Davis GL, Farraye F, Giannella RA, Malagelada JR, Steer ML (eds): Therapy of Digestive Disorders, ed 2. Saunders, 2006, pp 67-83.
16.
Ginés P, Arroyo V, Quintero E, et al: Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987;93:234-241.
17.
Salerno F, Badalamenti S, Incerti P, et al: Repeated paracentesis and i.v. albumin infusion to treat ‘tense' ascites in cirrhotic patients. A safe alternative therapy. J Hepatol 1987;5:102-108.
18.
Ruiz-del-Arbol L, Monescillo A, Jimenéz W, et al: Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997;113:579-586.
19.
Ginès P, Tito L, Arroyo V, et al: Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988;94:1493-1502.
20.
Ginès A, Fernández-Esparrach G, Monescillo A, et al: Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996;111:1002-1110.
21.
Moreau R, Valla DC, Durand-Zaleski I, et al: Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail. Liver Int 2006;26:46-54.
22.
Sola-Vera J, Miñana J, Ricart E, et al: Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003;37:1147-1153.
23.
Bernardi M, Caraceni P, Navickis RJ, Wilkes MM: Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology 2012;55:1172-1181.
24.
Cárdenas A, Ginès P: Management of refractory ascites. Clin Gastroenterol Hepatol 2005;3:1187-1191.
25.
Salerno F, Guevara M, Bernardi M, Moreau R, Wong F, Angeli P, Garcia-Tsao G, Lee SS: Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int 2010;30:937-947.
26.
Boyer TD, Haskal ZJ; American Association for the Study of Liver Diseases: The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology 2010;51:306.
27.
Lebrec D, Giuily N, Hadengue A, et al: Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. J Hepatol 1996;25:135-144.
28.
Rössle M, Ochs A, Gülberg V, et al: A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000;342:1701-1707.
29.
Ginès P, Uriz J, Calahorra B, et al: Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002;123:1839-1847.
30.
Sanyal AJ, Genning C, Reddy KR, et al: The North American study for the treatment of refractory ascites. Gastroenterology 2003;124:634-641.
31.
Salerno F, Merli M, Riggio O, et al: Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004;40:629-635.
32.
Narahara Y, Kanazawa H, Fukuda T, et al: Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial. J Gastroenterol 2011;46:78-85.
33.
Deltenre P, Mathurin P, Dharancy S, et al: Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis. Liver Int 2005;25:349-356.
34.
Albillos A, Bañares R, González M, et al: A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol 2005;43:990-996.
35.
DʼAmico G, Luca A, Morabito A, et al: Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 2005;129:1282-1293.
36.
Salerno F, Cammà C, Enea M, et al: Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007;133:825-834.
37.
Bai M, Qi XS, Yang ZP, Yang M, Fan DM, Han GH: TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. World J Gastroenterol 2014;20:2704-2714.
38.
Bellot P, Welker MW, Soriano G, et al: Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. J Hepatol 2013;58:922-927.
39.
Thomas MN, Sauter GH, Gerbes AL, Stangl M, Schiergens TS, Angele M, Werner J, Guba M: Automated low flow pump system for the treatment of refractory ascites: a single-center experience. Langenbecks Arch Surg 2015;400:979-983.
40.
Adebayo D, Bureau C, deRieu MC, et al: Alfapump system versus large volume paracentesis in the treatment of refractory ascites; results from a multicenter randomised controlled study (RCT). J Hepatol 2016;64:GS18A.
41.
Wong F, Gines P, Watson H, Horsmans Y, Angeli P, Gow P, Minini P, Bernardi M: Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol 2010;53:283-290.
42.
Wong F, Watson H, Gerbes A, Vilstrup H, Badalamenti S, Bernardi M, Ginès P; Satavaptan Investigators Group: Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut 2012;61:108-116.
43.
Ohki T, Sato K, Yamada T, Yamagami M, Ito D, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K: Efficacy of tolvaptan in patients with refractory ascites in a clinical setting. World J Hepatol 2015;7:1685-1693.
44.
Akiyama S, Ikeda K, Sezaki H, et al: Therapeutic effects of short- and intermediate-term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis. Hepatol Res 2015;45:1062-1070.
45.
Zhang X, Wang SZ, Zheng JF, et al: Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients. World J Gastroenterol 2014;20:11400-11405.
46.
Torres VE, Chapman AB, Devuyst O, et al: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367:2407-2418.
48.
Kalambokis G, Fotopoulos A, Economou M, et al: Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J Hepatol 2007;46:213-221.
49.
Singh V, Dhungana SP, Singh B, Vijayverghia R, Nain CK, Sharma N, Bhalla A, Gupta PK: Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. J Hepatol 2012;56:348-354.
50.
Krag A, Møller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F: Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 2007;46:1863-1871.
51.
Fimiani B, Guardia DD, Puoti C, D'Adamo G, Cioffi O, Pagano A, Tagliamonte MR, Izzi A: The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: a multicentric study. Eur J Intern Med 2011;22:587-590.
52.
Lenaerts A, Codden T, Meunier JC, et al: Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system. Hepatology 2006;44:844-849.
53.
Yang YY, Lin HC, Lee WP, et al: Association of the G-protein and α2-adrenergic receptor gene and plasma norepinephrine level with clonidine improvement of the effects of diuretics in patients with cirrhosis with refractory ascites: a randomised clinical trial. Gut 2010;59:1545-1553.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.